Andrew Schorr interviews Dr John Gribben of London's Barts Cancer Institute on the promise of drugs for PD1 and PDL1 that could train the immune system to kill cancer cells.
patientpower.info/video/cou...
I found this video particularly interesting because it covers one of proposed mechanisms by which cancerous B-Lymphocytes mediate the immune dysfunction via their control of T-cells by expressing PDL1 and how existing PD1 and PDL1 antibodies developed for solid tumours might be used to tackle CLL.
Lots of promise here, with plenty of potential tie in with existing and trial treatment regimens, but no indication of any funding for CLL unfortunately...
Neil